Mark Throsby
Director Ejecutivo en Alethiomics Ltd. .
Origen de la red de primer grado Mark Throsby.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
35
| Public Company | Biotechnology | 35 |
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands.
23
| Extinct | Pharmaceuticals: Major | 23 |
Ona Therapeutics SL
 Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation.
9
| Holding Company | Pharmaceuticals: Major | 9 |
Alethiomics Ltd.
 Alethiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Alethiomics Ltd. operates as a British biotechnology company. The company is based in Cambridge, UK. The company was founded in 2021 by Adam Joseph Mead, Bethan Psaila. The CEO is Mark Throsby.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Gadeta BV
 Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands.
4
| Subsidiary | Medical Specialties | 4 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Mark Throsby a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| University of Utrecht | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
| Erasmus University Rotterdam | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
Janssen Vaccines & Prevention BV
 Janssen Vaccines & Prevention BV Pharmaceuticals: MajorHealth Technology Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chairman Chief Operating Officer Corporate Officer/Principal Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| University of Amsterdam | College/University | Graduate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
ProFibrix BV
 ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member Chairman Chief Tech/Sci/R&D Officer | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
DCPrime BV
 DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer Director/Board Member | |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
| Hubrecht Organoid Technology Foundation | Director/Board Member Chairman Chief Executive Officer | ||
| University of Leiden | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| AVANTIUM N.V. | Industrial Machinery | Director/Board Member Director/Board Member | |
| KYMERA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member Founder | |
Nimbus Apollo, Inc.
 Nimbus Apollo, Inc. Pharmaceuticals: MajorHealth Technology Nimbus Apollo, Inc. provides drug discovery research services. The company is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Nimbus Therapeutics LLC
 Nimbus Therapeutics LLC BiotechnologyHealth Technology Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Private Equity Investor | |
Mimetas BV
 Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | Biotechnology | Chairman Director/Board Member | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | Corporate Officer/Principal President | |
Leyden Laboratories B.V.
 Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Miscellaneous Commercial Services | Founder Founder | |
| Humboldt-Universität zu Berlin | College/University | Doctorate Degree Doctorate Degree | |
| Pharmatching GmbH | Chief Executive Officer Chief Executive Officer | ||
Polpharma Biologics Utrecht BV
 Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk
 Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Miscellaneous Commercial ServicesCommercial Services Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk provides scientific services. It includes research and consultancy for government, businesses and organizations. The company was founded in 1932 and is headquartered in Delft, Netherlands. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Priothera Ltd.
 Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Biotechnology | Director/Board Member Chief Executive Officer | |
Oculis SA
 Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
| Gist-Brocades NV | Corporate Officer/Principal Corporate Officer/Principal | ||
| Radboud University Nijmegen | College/University | Doctorate Degree Doctorate Degree | |
| Nyenrode Business Universiteit | College/University | Director/Board Member Masters Business Admin | |
Q32 Bio, Inc.
 Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Biotechnology | Chairman Director/Board Member | |
| ARGENX SE | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Batavia Biosciences BV
 Batavia Biosciences BV Pharmaceuticals: MajorHealth Technology Batavia Biosciences BV provides biopharmaceutical process development services. It offers biopharmaceutical materials research and pre-clinical study services for biopharmaceutical clients. The firm services cover candidate selection, production of research materials, upstream and downstream process development, assay development, product characterization and clinical manufacturing and release. The company was founded in 2010 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer Founder | |
| Vrije Universiteit Amsterdam | College/University | Corporate Officer/Principal Graduate Degree | |
AM-Pharma Holding BV
 AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director/Board Member Director/Board Member | |
| AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Medlumics SL
 Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Medical Specialties | Director/Board Member Director/Board Member | |
| TIGENIX NV | Medical Specialties | Director/Board Member Director/Board Member |
Estadísticas
Internacional
| Países Bajos | 22 |
| Estados Unidos | 13 |
| Reino Unido | 4 |
| Bélgica | 4 |
| Suiza | 4 |
Sectorial
| Health Technology | 27 |
| Consumer Services | 10 |
| Commercial Services | 8 |
| Health Services | 3 |
| Producer Manufacturing | 2 |
Operativa
| Director/Board Member | 345 |
| Corporate Officer/Principal | 143 |
| Chairman | 96 |
| Independent Dir/Board Member | 81 |
| Chief Executive Officer | 63 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Jack Nielsen | 38 |
| Elaine Jones | 37 |
| Russell Greig | 31 |
| Florent Gros | 28 |
| Lionel Carnot | 27 |
| Mark Iwicki | 26 |
| Cees de Jong | 23 |
| John Paul de Koning | 21 |
| José Antonio Mesa Cejudo | 20 |
| Stephen Brown Davis | 20 |
| Pamela Klein | 19 |
| Mark de Boer | 19 |
| Anand Mehra | 18 |
| Björn Magnus Sjöstrand | 17 |
| Bill Lundberg | 17 |
- Bolsa de valores
- Insiders
- Mark Throsby
- Conexiones Empresas
